EyePoint Pharmaceuticals, Inc. EYPT 深 滬
等待開盤 10-22 09:30:00 美东时间
11.81
-0.220
-1.83%
華盛通- 最 高12.205
- 今 開12.04
- 成交量 116.11万股
- 最 低 11.77
- 昨 收 12.03
- 總市值 8.14亿
- 52周最高 14.91
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.91
- 委 比 -18.68%
- 總股本 6892.74万
- 歷史最高 39.40
- 量 比 0.52
- 振 幅 3.62%
- 歷史最低 2.19
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EyePoint files automatic mixed securities shelf
EyePoint Pharmaceuticals (NASDAQ:EYPT) filed automatic mixed securities shelf. Filing More on EyePoint Pharmaceuticals EyePoint Pharmaceuticals, Inc. (EYPT) Presents At Citi's Biopharma Back To School...
10-15 04:27
EyePoint Pharmaceuticals Initiates Pivotal Phase 3 Program For DURAVYU To Treat Diabetic Macular Edema; Expects First Patient Dosage In Q1 2026
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
10-15 04:03
EyePoint Announces Proposed Public Offering of Common Stock
EyePoint Pharmaceuticals announced an underwritten public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million. The offering aims to fund clinical development of DURAVYU™ for wet AMD and DME, with proceeds also supporting other pipeline initiatives. The transaction is subject to market conditions, with more details available via the SEC. EyePoint is focused on innovative treatments fo...
10-14 20:35
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema
DURAVYU™, developed by EyePoint Pharmaceuticals, has entered Phase 3 trials for treating diabetic macular edema (DME) with first patient dosing expected in Q1 2026. The active drug, vorolanib, inhibits both VEGF-mediated vascular permeability and IL-6 mediated inflammation, targeting the multifactorial nature of DME. Preclinical data supports multi-mechanism efficacy, aligning with Phase 2 results showing early and sustained visual improvements. ...
10-14 20:01
贝达药业:贝达取得在中国(包括香港、澳门和台湾)区域开发和商业化的EYP-190...
有投资者在深交所互动平台向贝达药业提问："请详细解释一下贵公司和Eyepoint是合作开发模式，当时签订授权协议时的首付款和里程碑以及分成是多少？"公司回复称...
09-11 16:10
EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy
Eyepoint Pharma (($EYPT)) announced an update on their ongoing clinical study. ...
08-16 00:25
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $27 Price Target
Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Buy and maintains $27 price target.
08-07 20:52
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
08-07 09:46
EyePoint Pharmaceuticals Q2 EPS $(0.85) Misses $(0.81) Estimate, Sales $5.333M Miss $6.627M Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.81) by 4.29 percent. This is a 46.55 percent decrease over losses of $(0.58) per
08-06 19:03
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
